ANTHELIOS 40
LOE Approachingavobenzone; ecamsule; octocrylene; titanium dioxide
NDATOPICALCREAM
Approved
Mar 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ANTHELIOS 40 (avobenzone; ecamsule; octocrylene; titanium dioxide). Approved for sunburn if used, decreases the risk of skin cancer, early skin aging caused by the sun. First approved in 2008.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTHELIOS 40 is a broad-spectrum topical sunscreen cream containing avobenzone, ecamsule, octocrylene, and titanium dioxide that protects against UVA and UVB radiation. It is indicated to decrease the risk of skin cancer, prevent sunburn, and reduce early skin aging caused by sun exposure. The product works through UV-absorbing and reflecting mechanisms to provide photoprotection.
LOE Approaching
As a mature topical product approaching loss of exclusivity, team sizes are likely stable to declining with focus shifting to cost management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.